[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  zohm [@zohmbastic](/creator/twitter/zohmbastic) on x 7901 followers Created: 2025-06-11 14:21:48 UTC $TSHA Taysha Gene Therapies price target raised to $XX from $X at Cantor Fitzgerald 10:20 TSHA Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Taysha Gene Therapies to $XX from $X and keeps an Overweight rating on the shares. After having attended the IRSF Rett Syndrome Scientific Meeting and spent additional time with Taysha management, the firm has "very high conviction" that the TSHA-102 pivotal trial will succeed, the analyst tells investors. Following data and regulatory path updates, the firm is increasing its view of the odds of success for TSHA-102 to XX% from 35%, the analyst noted. XXXXX engagements  **Related Topics** [stocks](/topic/stocks) [$tsha](/topic/$tsha) [Post Link](https://x.com/zohmbastic/status/1932805470860804502)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
zohm @zohmbastic on x 7901 followers
Created: 2025-06-11 14:21:48 UTC
$TSHA Taysha Gene Therapies price target raised to $XX from $X at Cantor Fitzgerald 10:20 TSHA Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Taysha Gene Therapies to $XX from $X and keeps an Overweight rating on the shares. After having attended the IRSF Rett Syndrome Scientific Meeting and spent additional time with Taysha management, the firm has "very high conviction" that the TSHA-102 pivotal trial will succeed, the analyst tells investors. Following data and regulatory path updates, the firm is increasing its view of the odds of success for TSHA-102 to XX% from 35%, the analyst noted.
XXXXX engagements
